Search This Blog

Thursday, January 13, 2022

Poor countries refuse 100 million COVID-19 vaccine doses set to expire

 Developing countries turned away some 100 million doses of COVID-19 vaccines because they were about to expire, the United Nations said.

The United Nations Children's Fund (Unicef), which plays a major role in the international Covax mechanism as the main logistics partner for the distribution of vaccines in disadvantaged countries, now says these countries will not accept vaccines that are too close to the expiry date.

"Over a hundred million doses were refused" in December, Unicef ​​Supply Division director Etleva Kadilli told the European Parliament's Development Committee, explaining that the majority of refusals were due to the expiry date.

She explained that these countries needed doses that could be stored long enough in order to plan vaccination campaigns and immunise "populations living in hard-to-reach areas and in fragile contexts".

The World Health Organization has repeatedly condemned rich countries for buying up the global supply of COVID-19 vaccines and only leaving doses that are set to expire for poorer countries.

At the end of December, Nigeria incinerated more than a million doses of AstraZeneca's COVID-19 vaccine which had been sent to the country despite them being set to expire.

Kadilli also explained that about a third of the doses provided by Covax were donations from European countries.

In October and November, 15 million doses donated by the European Union were refused by poor countries, 75% of which were AstraZeneca vaccines whose shelf life once the vaccines reached their destination was less than ten weeks.

More than 9.4 billion doses of vaccines have now been administered worldwide, WHO director-general Tedros Adhanom Ghebreyesus said on Thursday.

But at least 90 countries have not reached the 40% vaccine target that had been set for the end of 2021, he said, and more than 85% of Africa's population, or about one billion people, has not yet received a single dose of vaccine.

https://www.euronews.com/2022/01/13/poor-countries-refuse-100-million-covid-19-vaccine-doses-set-to-expire

National Guard to fill staff shortages in Wisconsin hospitals, nursing homes

 

  • Wisconsin Gov. Tony Evers announced Thursday National Guard troops will assist in filling staff shortages in the state’s hospitals and nursing homes.
  • The troops are being trained as certified nursing assistants.
  • "As we continue to see COVID-19 cases and hospitalizations surge, we are pursuing every available option to bring needed staffing support to Wisconsin’s health systems,” Evers said .

Wisconsin Gov. Tony Evers (D) announced Thursday National Guard troops will assist in filling staff shortages in the state’s hospitals and nursing homes amid a surge in hospitalizations related to COVID-19.  

Troops will deploy over a seven-week period beginning with the first 50 this week, while another 80 who are beginning training will deploy at the end of the month. An additional 80 members will begin training in early February. 

"As we continue to see COVID-19 cases and hospitalizations surge, we are pursuing every available option to bring needed staffing support to Wisconsin’s health systems,” Evers said in a news release 

Karen Timberlake from the department of health services said in the release support from the National Guard is “critical for supporting Wisconsin’s nursing homes.”  

“We continue to hear from our nursing home providers that they need more support to care for patients as our health system continues to be stressed by nearly two years of a global pandemic,” she continued. “Our new partnership with Madison College and the Wisconsin National Guard will help us ensure Wisconsinites have access to the care they need and help us increase critical healthcare capacity.” 

Wisconsin reported 13,004 new COVID-19 cases in the past day, which brings the seven-day average to nearly 10,000. The new seven-day average is nearly twice as high as the number two weeks ago, the release said.  

The state is also reporting a record number of patients with COVID-19 in intensive care units with 488. Currently, there are 2,278 total COVID-19 patients in the state, according to the release.  

https://thehill.com/changing-america/well-being/prevention-cures/589681-national-guard-to-fill-staff-shortages-in

Biogen eyes potential acquisitions

 

Biogen Inc is working with investment bank Goldman Sachs to find potential targets for acquisitions, Stat News reported on Thursday, citing an unnamed source.

The report said the company's board had warmed to the idea of acquisitions amid the turmoil surrounding its controversial Alzheimer's drug Aduhelm.

Biogen did not immediately reply to a Reuters request for comment on the report.

On Tuesday, the U.S. Centers for Medicaid and Medicare Services (CMS) said it would cover Aduhelm, and similar treatments, only for patients enrolled in approved clinical trials, threatening sales of the drug.

In a conference call with analysts on Thursday, Biogen Chief Executive Officer Michel Vounatsos said the management was engaging with the board on "tactical, short-term measures, but also strategic options".

Vounatsos was replying to a query on whether the company would consider any strategic options to protect shareholder value, especially in light of the Aduhelm controversy.

Aduhelm was approved by the U.S. Food and Drug Administration in June despite a vote by the agency's outside advisers that the treatment's clinical benefits had not been proven.

https://www.marketscreener.com/quote/stock/BIOGEN-INC-4853/news/Biogen-eyes-potential-acquisitions-Stat-News-37542589/

OraSure COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants

 

 OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab® COVID-19 rapid tests detect the Omicron variant as effectively as they detect the original SARS-CoV-2 strain and other previous variants of concern, including Delta, Alpha, Beta and Gamma. The Omicron variant studies were conducted using live SARS-CoV-2 virus at an independent, third-party laboratory and showed InteliSwab® detected the Omicron variant at the same viral load levels, or limit of detection, as previous variants that were tested.

“The global COVID-19 pandemic continues to evolve, and we will continue to monitor the situation and test InteliSwab® with all new variants of concern as they emerge,” said Lisa Nibauer, President of Diagnostics for OraSure. “As the Omicron variant erupts across the nation, this news should give consumers even more confidence when using the InteliSwab® test.”

Testing with InteliSwab® is simple: users swab their lower nostrils with the test stick, swirl it in a pre-measured solution, and see their result on the test stick in 30 minutes – with no instruments, batteries, smartphone or laboratory analysis needed to see the result. With less than one minute of “hands-on time,” it is as simple as “Swab, Swirl, and See.”

https://finance.yahoo.com/news/inteliswab-covid-19-rapid-tests-210500820.html

Leading eyecare company Bausch + Lomb files for an estimated $3 billion US IPO

 Bausch + Lomb, a leading supplier of contact lenses and eyecare products, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. However, this is likely a placeholder for a deal we estimate could raise up to $3 billion.


Bausch + Lomb states that it is a leading global eye health company, with a presence in approximately 100 countries and a comprehensive portfolio of over 400 products, and is fully integrated and built to serve its customers across the full spectrum of their eye health needs. Its lines of business include vision care and consumer healthcare, ophthalmic pharmaceuticals, and surgical. Since 2017, Bausch + Lomb has introduced more than 260 new products in approximately 60 countries.

The Vaughan, Canada-based company was founded in 1853 and booked $3.7 billion in sales for the 12 months ended September 30, 2021. It plans to list on the NYSE under the symbol BLCO. Bausch + Lomb filed confidentially on May 27, 2021. Morgan Stanley, Goldman Sachs, Citi, J.P. Morgan, Barclays, BofA Securities, Guggenheim Securities, Jefferies, Evercore ISI, Wells Fargo Securities, and Deutsche Bank are the joint bookrunners on the deal. No pricing terms were disclosed.

SPAC Sports & Health Tech Acquisition files for a $150 million IPO

 Sports & Health Tech Acquisition, a blank check company targeting the sports and health technology sectors, filed on Thursday with the SEC to raise up to $150 million in an initial public offering.


The Orlando, FL-based company plans to raise $150 million by offering 15 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50. At the proposed deal size, Sports & Health Tech Acquisition would command a market value of $188 million.

The company is led by Chairman Jon Voigtman, the former Co-CEO of RBC (Barbados) Trading Bank; CEO Andrew White, whose current roles include serving as Chairman of sports and health technology investment firm leAD Sports; and CFO Christopher Hubman, the CFO of Tiger Woods' TGR Ventures. Pro golfer Tiger Woods, former pro tennis player Caroline Wozniacki, and former NBA player David Lee are also involved with the SPAC.

The company plans to target the sports and health technology sectors, focusing on fan engagement, consumer-facing health and fitness technologies, and health & wellbeing.

Sports & Health Tech Acquisition was founded in 2021 and plans to list on the Nasdaq under the symbol LDSPU. The company filed confidentially on December 10, 2021. RBC Capital Markets is the sole bookrunner on the deal.

Business groups score victory with Supreme Court ruling

 Business groups celebrated Thursday after the Supreme Court blocked the Biden administration's COVID-19 vaccine-or-test mandate for large employers.  

Several trade associations sued to block the rule, which required businesses with 100 or more employees to mandate their workers get a COVID-19 vaccine or be tested weekly. Key components of the mandate went into effect on Monday, including a workplace mask requirement for unvaccinated workers.

David French, senior vice president of government relations at the National Retail Federation (NRF), called the ruling a “significant victory for employers.”

“NRF urges the Biden administration to discard this unlawful mandate and instead work with employers, employees and public health experts on practical ways to increase vaccination rates and mitigate the spread of the virus in 2022,” he said in a statement.

The high court voted 6-3 to block the vaccine-or-test mandate, with conservative justices arguing the Occupational Safety and Health Administration (OSHA) did not have the authority to issue the rule, which affects more than 80 million workers. The case will now be sent back to the 6th Circuit Court of Appeals. 

Business groups that sued to block the rule expressed concern that unvaccinated workers would leave their jobs rather than comply with the mandate amid a tight labor market. They also warned that employers would struggle to find enough COVID-19 tests for their workers.

“This is an important recognition that the OSHA rule is too broad,” said Doug Kantor, general counsel at the National Association of Convenience Stores. “Businesses are doing their part to promote vaccination and safety practices. We appreciate the Supreme Court recognizing that OSHA should not push regulatory requirements that cannot be met and will exacerbate the labor shortage.”

The Biden administration had stressed that the rule would save the lives of more than 6,500 workers and prevent roughly 250,000 hospitalizations over the next six months. 

“In blocking the vaccine-or-test rule for large employers, the court has placed millions of other essential workers further at risk, caving to corporations that are trying to rig the rules against workers permanently,” Mary Kay Henry, president of the Service Employee International Union, said in a statement. 

Labor lawyers generally favored the Biden administration’s arguments that it had the legal authority to enforce the regulations and that they were needed to slow the spread of COVID-19 in workplaces. But Thursday’s ruling indicates that the court’s conservative majority feels differently.

The Supreme Court ruling doesn’t block businesses from requiring their own workers to get the shot — large companies such as United Airlines and Tyson Foods have implemented far stricter rules — and challenges to private vaccine requirements have consistently failed in court. 

“The decision point is now squarely left to board rooms and chief executives to decide the fate of their own organizational policy, and their role in impacting how the next phase of the pandemic unfolds for the nation and the economy,” Ian Carleton Schaefer, chair of Loeb & Loeb’s employment and labor practice, said in an email. 

https://thehill.com/business-a-lobbying/business-a-lobbying/589675-business-groups-score-victory-with-supreme-court